Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not eligible for anthracycline-based chemotherapy.
In the Phase 2 EPCORE DLBCL-3 trial, fixed-duration epcoritamab monotherapy demonstrated encouraging efficacy. The study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58%. The safety profile was consistent with expectations in this patient group, with cytokine release syndrome (CRS) occurring in 71% of patients—most frequently during Cycle 1—and immune effector cell-associated neurotoxicity syndrome (ICANS) reported in 18%.
The Phase 1b/2 EPCORE NHL-2 trial evaluated epcoritamab in combination with R-mini-CHOP (rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone). Results showed an ORR of 93% and a CR rate of 86%, along with sustained minimal residual disease (MRD) negativity and durable remissions. The safety profile aligned with prior reports and the known profiles of epcoritamab and R-mini-CHOP. The most common Grade =3 treatment-emergent adverse events (TEAEs) included neutropenia (54%), serious infections (33%), and anemia (14%).
Both sets of results were presented in poster sessions at the European Hematology Association (EHA) 2026 Congress held in Stockholm, Sweden, from June 11-14.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.